Revolution Medicines, Inc. (RVMD)

Revolution Medicines' stock has experienced significant movement in the past six months. Key events impacting the stock price include the FDA Breakthrough Therapy Designation for zoldonrasib, acquisition speculation by Merck, Q4 2025 earnings report, clinical trial progress, insider trading, and analyst ratings. The stock price increased by 161.62% from March 31, 2025, to March 27, 2026, but decreased by 9.13% in March 2026.

As a clinical-stage biotechnology company, Revolution Medicines, Inc. does not experience typical demand seasonality for its products or services. The demand for its pipeline is driven by the prevalence of RAS-addicted cancers and the need for effective treatments. The company's progress is primarily influenced by clinical trial outcomes and regulatory approvals.

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing targeted therapies for cancers driven by RAS mutations. The company's pipeline includes RAS(ON) inhibitors and RAS companion inhibitors. Key product candidates include daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805).

Revolution Medicines, Inc. is headquartered in Redwood City, California, USA. The company's stock is traded on the NASDAQ Global Select exchange in the US, and also listed on several European stock exchanges, including Stuttgart, Dusseldorf, Frankfurt, Munich, Hamburg, Berne, and Milan. Its geographic footprint is primarily defined by its research and development activities and financial market presence.

Revolution Medicines' brand reputation has been shaped by its scientific advancements and clinical development progress. Positive events include receiving FDA Breakthrough Therapy Designation for zoldonrasib, advancing its RAS(ON) inhibitor pipeline, forming strategic partnerships, and securing substantial royalty and loan funding. Challenges include missing Q4 2025 EPS estimates, the reported withdrawal of Merck from potential acquisition talks, and insider selling.

Revolution Medicines, Inc. has a significant level of institutional ownership, ranging from approximately 85.44% to 94.34%. Major institutional owners include Vanguard Group Inc, Farallon Capital Management Llc, and Janus Henderson Group Plc. Individual insiders own approximately 2.24% to 2.28% of the stock, with CEO Mark Goldsmith being a notable insider. Public companies and retail investors hold about 12.32% to 12.88% of the shares.